Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/25686
Tipo
PreprintDerechos de autor
Acceso abierto
Colecciones
- INI - Preprint [96]
Metadatos
Mostrar el registro completo del ítem
RECOVERY OF BONE MINERAL DENSITY AFTER DISCONTINUATION OF TENOFOVIR-BASED HIV PRE-EXPOSURE PROPHYLAXIS
Tenofovir
Emtricitabine
Bone Density
Absorptiometry, Photon
https://www.arca.fiocruz.br/handle/icict/46310
Autor
Afiliación
University of California, San Francisco, San Francisco, California, USA.
University of California, San Francisco, San Francisco, California, USA.
University of Washington, Seattle Washington, USA.
University of Colorado, Denver, Aurora, Colorado, USA.
Investigaciones Médicas en Salud, Lima, Peru.
Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
Bridge HIV, San Francisco Department of Public Health, San Francisco, California, USA.
Desmond Tutu HIV Foundation, Cape Town, South Africa.
Universidade Federal do Rio de Janeiro. Hospital Escola São Francisco de Assis. Projeto Praça Onze, Rio de Janeiro, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brasil.
Gladstone Institute of Virology and San Francisco AIDS Foundation, San Francisco, California, USA
University of California, San Francisco, San Francisco, California, USA.
University of Washington, Seattle Washington, USA.
University of Colorado, Denver, Aurora, Colorado, USA.
Investigaciones Médicas en Salud, Lima, Peru.
Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
Bridge HIV, San Francisco Department of Public Health, San Francisco, California, USA.
Desmond Tutu HIV Foundation, Cape Town, South Africa.
Universidade Federal do Rio de Janeiro. Hospital Escola São Francisco de Assis. Projeto Praça Onze, Rio de Janeiro, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brasil.
Gladstone Institute of Virology and San Francisco AIDS Foundation, San Francisco, California, USA
Resumen en ingles
Background: Oral tenofovir disoproxil fumarate (TDF) for HIV prevention and treatment is associated with decreases in bone mineral density (BMD). Previous reports suggest that these changes may be reversible after discontinuation of TDF. Setting: A metabolic substudy of 498 participants in a randomized, placebo-controlled HIV prevention trial of oral co-formulated TDF with emtricitabine (TDF/FTC, Truvada®) for HIV preexposure prophylaxis (PrEP) enrolling a global sample of men who have sex with men and trans women. Methods: Participants underwent dual X-ray absorptiometry (DXA) to quantify bone mineral density (BMD) in the hip and spine during PrEP and at 2 visits after stopping (median of 23 and 79 weeks postPrEP, respectively). Results are stratified by pharmacologic measure of TDF/FTC adherence. Results: There was no significant difference in change in hip/spine BMD at any timepoint between placebo and those with low adherence. Adherent participants had a mean (standard error) BMD change at TDF/FTC discontinuation of -1.02% (0.24) in the hip and -1.84% (0.36) in the spine. After stop, annualized BMD increases of 1.13% per year (0.27) in hip and 1.81% per year (0.36) in spineBMD were observed in adherent participants compared with 0.19% (0.16) and 0.74% (0.21) in the placebo group, respectively (p=0.003, both comparisons). On average, BMD returned to baseline levels by 1 year after PrEP stop. Recovery was consistent across age, baseline BMD z-score and treatment duration.
Palabras clave en ingles
Pre-Exposure ProphylaxisTenofovir
Emtricitabine
Bone Density
Absorptiometry, Photon
Compartir